iRhythm Technologies (IRTC) Stock Forecast, Price & News

iRhythm Technologies (NASDAQ:IRTC) Frequently Asked Questions

Is iRhythm Technologies a buy right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for iRhythm Technologies in the last year. There are currently 1 sell rating and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" iRhythm Technologies stock.
View analyst ratings for iRhythm Technologies or view top-rated stocks.

When is iRhythm Technologies' next earnings date?

iRhythm Technologies is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for iRhythm Technologies.

How were iRhythm Technologies' earnings last quarter?

iRhythm Technologies, Inc. (NASDAQ:IRTC) issued its quarterly earnings data on Thursday, May, 5th. The company reported ($0.80) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.06) by $0.26. The company had revenue of $92.40 million for the quarter, compared to the consensus estimate of $86.76 million. iRhythm Technologies had a negative trailing twelve-month return on equity of 34.55% and a negative net margin of 36.43%. The firm's revenue was up 24.4% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.95) EPS.
View iRhythm Technologies' earnings history.

What guidance has iRhythm Technologies issued on next quarter's earnings?

iRhythm Technologies issued an update on its FY 2022 earnings guidance on Monday, May, 23rd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $410.00 million-$420.00 million, compared to the consensus revenue estimate of $407.15 million.

What price target have analysts set for IRTC?

9 equities research analysts have issued twelve-month price objectives for iRhythm Technologies' stock. Their forecasts range from $105.00 to $192.00. On average, they expect iRhythm Technologies' stock price to reach $156.82 in the next year. This suggests a possible upside of 11.5% from the stock's current price.
View analysts' price targets for iRhythm Technologies or view top-rated stocks among Wall Street analysts.

Who are iRhythm Technologies' key executives?

iRhythm Technologies' management team includes the following people:

• Mr. Quentin S. Blackford, Pres, CEO & Director (Age 43, Pay $671.81k)
• Mr. Douglas J. Devine, COO, CFO & Sec. (Age 52, Pay $1.14M) (LinkedIn Profile)
• Mr. Mark J. Day Ph.D., Chief Technology Officer (Age 51, Pay $718.76k)
• Mr. Daniel G. Wilson, Exec. VP of Strategy, Corp. Devel. & Investor Relations (Age 40, Pay $670.09k)
• Mr. David A. Vort, Chief Commercial Officer (Age 56, Pay $896.16k)
• Mr. Patrick Michael Murphy J.D., Chief Legal Officer (Age 43)
• Ms. Judith C. Lenane MHA, RN, Chief Clinical Officer & Exec. VP of Products (Age 63)
• Ms. Dietra N. Jones, Exec. VP of Clinical Operations
• Mr. Mazi Kiani, Sr. VP of Quality & Regulatory

What is Kevin M. King's approval rating as iRhythm Technologies' CEO?

20 employees have rated iRhythm Technologies CEO Kevin M. King on Glassdoor.com. Kevin M. King has an approval rating of 91% among iRhythm Technologies' employees. This puts Kevin M. King in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of iRhythm Technologies' key competitors?

Some companies that are related to iRhythm Technologies include Insulet (PODD), Teleflex (TFX), Abiomed (ABMD), NovoCure (NVCR), Globus Medical (GMED), ShockWave Medical (SWAV), Penumbra (PEN), Integra LifeSciences (IART), Inspire Medical Systems (INSP), Tandem Diabetes Care (TNDM), ICU Medical (ICUI), Inari Medical (NARI), Merit Medical Systems (MMSI), Haemonetics (HAE) and NuVasive (NUVA).
View all of IRTC's competitors.

What other stocks do shareholders of iRhythm Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other iRhythm Technologies investors own include NVIDIA (NVDA), Alibaba Group (BABA), Salesforce (CRM), Square (SQ), Teladoc Health (TDOC), Trade Desk (TTD), Advanced Micro Devices (AMD), Intel (INTC), Broadcom (AVGO) and Boeing (BA).

When did iRhythm Technologies IPO?

(IRTC) raised $76 million in an IPO on Thursday, October 20th 2016. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan and Morgan Stanley acted as the underwriters for the IPO and Canaccord Genuity and BTIG were co-managers.

What is iRhythm Technologies' stock symbol?

iRhythm Technologies trades on the NASDAQ under the ticker symbol "IRTC."

Who are iRhythm Technologies' major shareholders?

iRhythm Technologies' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Sands Capital Management LLC (10.15%), Vanguard Group Inc. (9.11%), BlackRock Inc. (7.03%), Capital Research Global Investors (4.74%), Mackenzie Financial Corp (3.95%) and Invesco Ltd. (2.70%). Company insiders that own iRhythm Technologies stock include Daniel G Wilson, David A Vort, Douglas Devine, Kevin M King, Mark J Day and Raymond W Scott.
View institutional ownership trends for iRhythm Technologies.

Which institutional investors are selling iRhythm Technologies stock?

IRTC stock was sold by a variety of institutional investors in the last quarter, including Mackenzie Financial Corp, Wellington Management Group LLP, Vident Investment Advisory LLC, Bank of New York Mellon Corp, Blair William & Co. IL, Eversept Partners LP, Sands Capital Management LLC, and State Street Corp. Company insiders that have sold iRhythm Technologies company stock in the last year include Daniel G Wilson, David A Vort, Douglas Devine, and Kevin M King.
View insider buying and selling activity for iRhythm Technologies or view top insider-selling stocks.

Which institutional investors are buying iRhythm Technologies stock?

IRTC stock was bought by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, Capital Research Global Investors, Atika Capital Management LLC, Eminence Capital LP, Goldman Sachs Group Inc., Assenagon Asset Management S.A., Invesco Ltd., and Lisanti Capital Growth LLC.
View insider buying and selling activity for iRhythm Technologies or or view top insider-buying stocks.

How do I buy shares of iRhythm Technologies?

Shares of IRTC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is iRhythm Technologies' stock price today?

One share of IRTC stock can currently be purchased for approximately $140.61.

How much money does iRhythm Technologies make?

iRhythm Technologies has a market capitalization of $4.19 billion and generates $322.83 million in revenue each year. The company earns $-101.36 million in net income (profit) each year or ($4.210010) on an earnings per share basis.

How many employees does iRhythm Technologies have?

iRhythm Technologies employs 1,700 workers across the globe.

What is iRhythm Technologies' official website?

The official website for iRhythm Technologies is www.irhythmtech.com.

How can I contact iRhythm Technologies?

iRhythm Technologies' mailing address is 650 TOWNSEND STREET SUITE 500, San Francisco CA, 94103. The company can be reached via phone at (415) 632-5700 or via email at [email protected].